News & Updates
Stay up to date with the events unfolding around Spectral Platforms and our groundbreaking technology. Blog coming soon.
Refocusing efforts on SARS CoV19
The InSpector-01 and BloodFAST tools were supposed to roll out this summer. However, those plans have been impacted by SARS CoV19.
We are informed by the USPTO of a “notice of allowance” on our patent application “Albumin-based non-covalent complexes and methods of use thereof”
Spectral Platforms is one of 10 Step 1 winners on the AMR challenge Winners were announced, 3/27/2017..
Qsub on InSpector-01 submitted to the FDA
Clinical study of InSpector-01 ends at US site
Company closes Series A3 investment round
Patent application “Albumin-based non-covalent complexes and methods of use thereof” published at USPTO site
Nov 11, 2016
Clinical study of InSpector-01 begins at US site
Clinical study of InSpector-01 ends at UK site
Clinical study of InSpector-01 begins at UK site
Company closes Series A2 investment round
Study of InSpector-01 with artificially spiked samples ends at UK site
Company closes Series A investment round
Patent application “Rapid detection of metabolic activity” published at USPTO site
Initial PreIDE submission on InSpector-01 to the FDA
January, 2012
Initial clinical study on screened biomarker conducted at US site